References

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

10.1016/s1470-2045(20)30443-5 · 2020 · External reference

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

10.1038/s41467-023-37648-w · 2023 · External reference

Obinutuzumab versus rituximab immunochemotherapy in previously untreated iNHL: final results from the GALLIUM study

10.1097/hs9.0000000000000919 · 2023 · External reference

Obinutuzumab for the first-line treatment of follicular lymphoma

10.1056/nejmoa1614598 · 2017 · External reference

Unresolved reference

2013 · External reference

Obinutuzumab can be administered as a 90-minute short duration infusion in patients with previously untreated follicular lymphoma: GAZELLE end of induction analysis

10.1097/hs9.0000000000000860 · 2023 · External reference

Evaluation of safety outcomes with transitioning obinutuzumab from standard rate to short duration infusion in patients with chronic lymphocytic leukemia

10.1080/10428194.2024.2341999 · 2024 · External reference

Unresolved reference

2022 · External reference

Venetoclax and obinutuzumab in patients with CLL and coexisting conditions

10.1056/nejmoa1815281 · 2019 · External reference

Unresolved reference

2022 · External reference

Increasing operational capacity and reducing costs of rituximab administration: a costing analysis

10.1002/acr2.11133 · 2020 · External reference

Patient preference for a shorter infusion time of rituximab in RA [abstract]

10.1136/annrheumdis-2015-eular.2035 · 2015 · External reference

Sixty-minute infusion rituximab protocol allows for safe and efficient workflow

2016 · External reference

Ultrafast 30-min infusion of a rituximab biosimilar (Truxima)

10.1002/jha2.812 · 2023 · External reference

Premedication with montelukast and rupatadine decreased rituximab infusion time, rate, severity of reactions and use of rescue medications

10.1002/ijc.32985 · 2020 · External reference